June 12, 2026

Why Practices Join Hospital Systems

Interviews with hospital leaders and employed physicians highlighted financial pressures, perceived care-integration benefits, and unresolved operational tensions following acquisition.

Conexiant

June 12, 2026

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 01, 2026

Top 10 States for Early-Career Physicians

These 10 states reported physician residency completion totals, physician retention rates, or residency Match fill rates identified in graduate medical education data.

Conexiant

May 29, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Conexiant

May 29, 2026

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Conexiant

May 28, 2026

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

Conexiant

May 28, 2026

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Conexiant

May 27, 2026

Top 10 Evidence-Based Essentials in Family Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Conexiant

May 22, 2026

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

Conexiant